TR-002 for Advanced Cancer
Phase 1
52
about 4.3 years
18+
1 site in CA
About this study
This trial is testing the safety and side effects of TR-002 in people with advanced, unresectable or metastatic solid tumors and unresectable or metastatic, refractory pancreatic adenocarcinoma. The goal is to determine the best dose of TR-002 that can be safely used in this type of cancer treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take TR-002
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Incidence of dose limiting toxicity (DLTs), Number of participants experiencing treatment-related adverse events
Secondary: Apparent clearance/bioavailability, Half-life, Objective response rate (ORR), Overall survival, Peak Plasma Concentration (Cmax), Progression free survival
Oncology